- Tỉ lệ bề dày lớp nội trung mạc động mạch cảnh dương tính và microalbumin niệu dương tính ở nhóm GOLD 12 (8,62%) thấp hơn so vớ
TÀI LIỆU THAM KHẢO
TIẾNG VIỆT
1.Lê Văn Bàng (2011), “Bệnh phổi tắc nghẽn mạn tính”, Giáo trình sau đại học
chuyên ngành nội hô hấp, Nhà xuất bản Đại học Huế, tr: 92-123.
2.Ngô Quý Châu (2012), Bệnh phổi tắc nghẽn mạn tính, Nhà xuất bản Y học. 3.Lê Thị Tuyết Lan (2005), Hô Hấp Ký, Nhà xuất bản Y học.
4.Đỗ Thị Tường Oanh (2013), “COPD và các bệnh đi kèm”, Tiếp cận mới
trong chẩn đoán và điều trị bệnh lý hô hấp, Hội nghị thường niên nội hô
hấp thành phố Hồ Chí Minh, tr: 43-48.
5.Đỗ Trung Phấn (2005), “Phương pháp xác định fibrinogen”, Kỹ thuật xét
nghiệm huyết học và truyền máu ứng dụng trong lâm sàng, tr: 84 - 85.
6.Nguyễn Phước Bảo Quân (2012), “Siêu âm doppler động mạch cảnh”, Siêu
âm Doppler mạch máu tập 1, Nhà xuất bản Đại học Huế, tr: 171-235.
7.Đinh Ngọc Sỹ và cộng sự (2007), “Nghiên cứu tình hình dịch tễ học bệnh phổi tắc nghẽn mạn tính tại Việt nam”, Kỉ yếu Hội nghị Nội khoa toàn
quốc, tr: 45-49.
8.Nguyễn Văn Thành, Cao Thị Mỹ Thuý (2011), “Hô hấp ký”, Phác đồ điều
trị và quy trình một số kỹ thuật trong thực hành nội khoa bệnh phổi, Nhà
xuất bản Y học, tr: 96-101.
9.Võ Văn Thắng, Hoàng Đình Huề (2011), “Sử dụng phần mềm thống kê SPSS”, Giáo trình đào tạo đại học và sau đại học trong ngành y, Nhà xuất bản Đại học Huế.
10.Nguyễn Hải Thủy (2008), “Rối loạn lipid máu”, Giáo trình sau đại học
TIẾNG ANH
11.Abdushi S.A, Krgezice F.U, Nazreku F.D (2013), “Increased carotid intima-media thickness associated with high hs-CRP levels is a predictor of unstable coronary artery disease”, Cardiovascular journal of Africa, 24, pp. 270-273.
12.Albu A, Fodor D, Poanta L et al (2012), “Markers of systemic involvement in chronic obstructive pulmonary disease”, Rom J Intern Med, 50, pp. 129-134.
13.Alpsoy S, Akyuz A, Mutlu L et al (2013), “Serum fetuin-A levels are associated with carotid intima media thickness in patients with normotensive chronic obstructive pulmonary disease”, Cardiology
Journal, Doi: 10.5603/CJ.a2013.0060, 2013-05-12.
14.Alvarez F.V, Barba G.P, Seco J.G et al (2011), “Vascular dysfunction and systemic inflammation in patients with COPD”, ERJ, 38(55), pp. 735. 15.American Lung Association (2013),“Trend in COPD (Chronic bronchitis
and emphysema): Morbidity and mortality”, American Lung Association. 16.American Medical Association (2001), “Executive summary of the third
report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)”, JAMA, 258, pp. 2486-2497.
17.Anthonisen N.R, Connett J.E, Enright P.L et al (2002), “Hospitalization and mortality in the Lung Health Study”, Am J Respir Crit Care Med, 166, pp. 333-339.
18.Anthonisen N.R, Connett J.E, Killy J.P et al (1994), “Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1”, JAMA, 272(19), pp. 1497-1505.
19.Arsovski Z, Gavrilovski M, Kavea B et al (2013), “Carotid wall intima- media thickness (IMT ĐMCA) in COPD patients”, Annual Congress
20.Augusti A.G.N, Noguera A, Sauleda J et al (2003), “Systemic effects of chronic obstructive pulmonary disease”, Eur Respir J, 21, pp. 347-360. 21.Barr Graham R (2011), “The epidemiology of vascular dysfunction
relating to chronic obstructive pulmonary disease and emphysema”, Proc
Am Thorac Soc, 8, pp. 522-527.
22.Barr R.G, Ahmed F.S, Carr J.J et al (2012), “Subclinical atherosclerosis, airflow obstruction and emphysema: the MESA Lung Study”, Eur Respir J, 39(4), pp. 846-854.
23.Besir F.H, Aydin Y.L, Yazgan O et al (2012), “Evaluation of carotid intima media thickness in chronic obstructive pulmonary disease patients”, Tuberk Toraks, 60(3), pp. 238-245.
24.Bulcun E, Mehmet E, Aydanur E et al (2013), “Microalbuminuria in chronic obstructive pulmonary disease”, Journal of chronic obstructive
pulmonary disease, 10, pp. 186-192.
25.Calverley P.M.A, Anderson J.A, Celli B.C et al (2007), “Salmeterol and fluticasone propionate and survival in chronic obstructive pulmomary disease”, N Engl J Med, 356, pp. 775-789.
26.Campbell J.L, Calverley P.M, Lamb D, Flenley D (1982), “The renal glomerulus in hypoxic cor pulmonale”, Thorax, 37, pp. 607-611.
27.Cao J.J, Arnold M.A, Manolio T.A et al (2007), “Association of carotid artery intima-media thickness, plaques, and C- reactive protein with future cardiovascular disease and all cause mortality: The Cardiovascular Health Study”, Circulation, 116, pp. 32-38.
28.Casanova C, Tores J.P, Navarro J et al (2010), “Microalbuminuria and hypoxemia in patients with chronic obstructive pulmonary disease”, Am J
Respir Crit Care Med, 182, pp. 1004-1010.
29.Chandra D, Champion H, Nemcova S et al (2012), “Smokers with carotid altherosclerosis have evidence of endothelial dysfunction”, Am J Respir
30.Chaouat A, Savale L, Chouaid C et al (2009), “Role for interleukin-6 in COPD - related pulmonary hypertension”, Chest, 136(3), pp. 678-687. 31.Currie G, Delles C (2014), “Proteinuria and its relation to cardiovascular
disease”, International journal of nephrology and renovascular disease, 7, pp. 13-24.
32.Dahl M, Vastbo J, Lange P et al (2006), “C-reactive protein as a preditor of prognosis in chronic obstructive pulmonary disease”, Am J Repir Crit
Care Med, 175, pp. 250-255.
33.Demertzis L, Senior R.M, Carlstrom L et al (2010), “Chronic Obstructive Pulmonary Disease”, The Washington manual of medical therapeutics, pp.272-280.
34.Ebrahim S, Papacosta O, Whincup P et al (1999), “Carotid Plaque, intima media thickness, cardiovascular risk factor, and prevalent cardiovascular disease in men and women: the British Regional Heart Study”, Stroke, 30, pp. 841-850.
35.Ferrari R, Tannis S.E, Caram L.M.O (2013), “Three-year follow-up interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease”, Respiratory Research, 14(24), doi: 10.1186/1465-9921-14-24. 36.Gan W.Q, Man F.S.P, Senthilselvan A, Sin D.D (2004), “Association
between chronic obstructive pulmonary disease and systemic inflammation: a systematic rewiew and a meta-analysis”, Thorax BMJ, 59, pp. 574-580. 37.Gestel Y.R.BM, Flu W.J, Kuijk J.P et al (2010), “Association of COPD
with carotid wall intima-media thickness in vascular surgery patients”,
Respir Med, 104(5), pp. 712-7166.
38.GOLD (2013), “Pocket guide to COPD diagnosis, management and prevention”, GOLD.
39.Harris B, Klein R, Herold M.I et al (2012), “The Association of systemic microvascular changes with Lung function and Lung density: A cross- section study”, Plus ONE, doi: 10.1371.
40.Hillege H.L, Fidler V, Diercks G.F.H et al (2002), “Urinary albumin excretion predicts cardiovascular and noncardiovasculas mortality in general population”, Circulation, 106, pp. 1777-1782.
41.Husein M, Adl T.E, Daiyumy R et al (2012), “Subclinical atherosclerosis in COPD smokers: An Egyptian Randomized Controlled study”, Journal
of American Science, 8, pp. 422-429.
42.Incalzi R.A, Battaglia S, Paglino G et al (2010), “Chronic renal failure: a neglected comorbidity of COPD”, Chest, 137, pp. 831-837.
43.Iwamoto H, Yokoyama A, Kitahara Y et al (2009), “Airflow limitation in smokers is associated with subclinical atherosclerosis”, Am J Respir Crit
Care Med, 179, pp.35-40.
44. Jankowich M, Choudhary G, Klinger J.R et al (2012), “Relationship between lung function and microalbuminuria: Data from the third National Health And Nutrition Examination Survey (NHANES III)”,
Am J Respir Crit Care Med, 185, A6042-50.
45.John M, Hussain S, Prayle A et al (2013), “Target renal damage: the microvascular associations of increased aortic stiffness in patients with COPD”, Respiratory Research, 14(31), pp. 1-7.
46.Joppa P, Petrasova D, Stancak B et al (2006), “Systemic inflammation in patients with COPD and pulmonary hypertention”, Chest, 130, pp. 326-333. 47.Karakas O, Cullu N, Karakas E et al (2013), “Evaluation of carotid
intima-media thickness in the patients with chronic obstructive pulmonary disease”, Acta Medica Mediterranea, pp. 29:265.
48.Kastelein J.P, Steeg W.A, Holme I et al (2008), “Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment”,
Circulation, 117, pp. 3002-3009.
49.Kim S.J, Yoon D.W, Lee E.J et al (2011), “Carotid atherosclerosis in patients with untreated chronic obstructive pulmonary disease”, Int J
50.Kolsum U, Roy K, Starkey C et al (2009), “The repeatability of interleukin-6, tumor necrosis factor-α, and C-reactive protein in COPD patients over year”, International Journal of Chronic Obstructive
Pulmonary Disease, 4, pp. 149-156.
51.Komurcuoglu A, Kalenci S, Kalenci D et al (2003), “Microalbuminuria in chronic obstructive pulmonary disease”, Monaldi Arch Chest Dis, 59(4), pp. 269-272.
52.Lahousse U.L, Bouwhuijsen Q.A, Loth D.W et al (2013), “Chronic obstructive pulmonary disease and lipid core carotid artery plaques in the elderly: the Rotterdam Study”, Am J Respir Crit Care Med, 187, pp. 58-64. 53.Long H, Lou H, Chen P, Li Y (2011), “Correlation among the levels of C-
reactive protein and interleukin-18, quality of life, and lung function in patients with chronic obstructive pulmonary disease”, Zhong Nan Da Xue
Bao Yi Xue Ban, 36 (11), pp. 1090-1096.
54.Ma Z, Liu Y, Xu Y et al (2013),“Impaired Lung Function is associated with increased carotid intima-media thickness in middle-aged and elderly Chinese”, Plos One, 8(2), pp. e53153.
55.Maclay J.D, Allister D.A, Mills N.L et al (2009), “Vascular dysfunction in COPD”, Am J Respir Crit Care Med, 180, pp. 513-520.
56.Malerba M and Romanelli G (2009), “Early cardiovascular involvement in chronic obstructive pulmonary disease”, Monaldi Arch Chest Dis, 71, pp. 59-65.
57.Man S.F.P, Connett J.E, Anthonisen N.R et al (2006), “C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease”,
Thorax, 61, pp. 849-853.
58.Mannino David M, Doherty Dennis E, Buist Sonia A (2006), “GOLD classification of lung disease and mortality: findings from the Atherosclerosis Risk In Communities (ARIC study)”, Respiratory
59. McNicholas W.T (2009),“Chronic obstructive pulmonary disease and obstructive sleep apnea”, Am J Respir Care Med, 180, pp. 692-700. 60.MeiLan K.H, (2011), “Update in chronic obstructive pulmonary disease in
2010”, Am J Respir Crit Care Med, 183, pp. 1311-1315.
61.Miller J, Edwards L.D, Agusti A et al (2013), “Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort”, Respir Med, 107(9), pp. 1376-84.
62.Nakamura M, Onoda T, Itai K et al (2004), “Association between serum C-reactive protein levels and microalbuminuria: A population-based cross-sectional study in northern Iwate, Japan”, The Japanese Society of
internal medicine, 4310), pp. 919-925.
63.National Kidney Foundation (2007), “KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease”, National Kidney Foundation.
64.O’Leary Daniel H and Burke Gregory L (1999), “Carotid-Artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults”, N Engl J Med, 340, pp.14-22.
65.Ogata T, Yamagishi M, Seguchi O et al (2005), “Atherosclerosis found on carotid ultrasonography is associated with atherosclerosis on coronary intravascular ultrasonography”, J Ultrasound Med, Vol 24, pp. 469-474. 66.Oudijk E.J.D, Lammers J.W.J, Koenderman L et al (2003), “Systemic
inflammation in chronic obstructive pulmonary disease”, Eur Respir J, Suppl 46, 5S-13S.
67.Ozgen A, Arslan K.I, Serter S et al (2013), “Metabolic syndrome and carotid intima-media thickness in chronic obstructive pulmonary”,
Multidisciplinary Respiratory Medicine, pp. 8-61.
68.Petty T.L (2006), “The history of COPD”, Int J Chron Obstruct Pulmon
Dis, 1(1), pp. 3-14.
69.Plata P.V.M, Livnat G, Girish M et al (2007), “Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD”, Chest, 131(1), pp. 37-43.
70.Platini P, Mormino P, Dorigatti F et al (2006), “Glomerular hyperfiltration predicts the development of microalbuminuria in stage 1 hypertention: The HARVEST”, Kidney International, 70, pp. 578-584.
71.Probeha P, Skyba P, Joppa P et al (2011), “Carotid intima-media thickness in patients with chronic obstructive pulmonary disease”, Bratisl
Lek Listy, 112(1), pp. 24-28.
72.Raherison C and Girodet P.O (2009), “Epidemiology of COPD”, Eur
Respir Rev, 18 (114), pp. 213-224.
73.Rio F.G, Miravitlles M, Soriano J.B et al (2010), “Systemic inflammation in chronic obstructive pulmonary disease: a population-based study”,
Respiratory research, 11(63), pp. 2-15.
74.Robert W.C (2002), “Body mass index as an indicator of obesity”, Asia
Pacific J Clin Nutri, 11, pp. S684-S686.
75.Romundstad S, Holmen J, Hallan H et al (2002), “Microalbuminuria cardiovascular disease and risk factors in a nondiabetic- nonhypertensive population. The Nord-Trondeglag Health Study (HUNT, 1995-97), Norway”, Journal of Internal Medicine, 252, pp. 164-172.
76.Ross R (1993), “The pathogenesis of atherosclerosis: a perspective for the 1990s”, Nature, 362, pp. 801-809.
77.Ruijter H.M.D, Dekker J.M, Eijkermans J et al (2012), “Common carotid intima-media thickness measurements in cardiovascular risk prediction: A meta-analysis”, JAMA, 308(8), pp. 796-803.
78.Saha A, Sinha K.P, Paul R et al (2011), “Study of carotid intima media thickness and its correlation with novel risk factors in ischemic stroke”,
79.Satchell S.C and Tooke J.E (2008),“What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium?”,
Diabetologia, 51(5), pp. 714-725.
80.Schunemann H.J, Grant B, Trevisan M (2000), “Pulmonary function is a long-term predictor or mortality in the general population”, Chest, 118, pp. 656-664.
81.Shibata Y, Abe S, Inoue S et al (2013),“Relationship between plasma fibrinogen levels and pulmonary function in the Japanese population: The Takahata study”, Int J Med Sci, 10, pp. 1530-36.
82.Shirai T, Suda T, Inui N, Chida K (2010), “Correlation between peripheral blood T-cell profiles and clinical and inflammatory parameters in stable COPD”, Allergology International, 59, pp. 75-82.
83. Sin D.D, Anthnisen N.R, Soriano J.B, Agusti A.G (2006), “Mortality in COPD: role of comorbidities”, Eur Respir J, 28, pp. 1245-1257. 84.Sin Don D and Man Paul S.F (2003), “Why are patients with chronic
obstructive pulmonary disease at increased risk of cardiovascular disease? The potential role of systemic inflammation in chronic obstructive pulmonary disease”, Circulation, 107, pp.1515-1519.
85.Sin Don D and Man Paul S.F (2005), “Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality”, Proc
Am Thorac Soc, 2, pp. 8-11.
86.Stehouwer Coen D.A and Smulders Yvo M (2006), “Microalbuminuria and risk for cardiovascular disease: Analysis of potential mechanisms”, J
Am Soc Nephrol, 17, pp. 2106-2111.
87.Stein J.H, Korcarz C.E, Hurst R.T et al (2008),“Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography carotide intima - media thickness task force endorsed by the Society for Vascular Medicine”, Journal of the American Society of
88.Stephan F, Eeden S.F, Sin D.D (2008), “Chronic Obstructive pulmonary disease: A chronic systemic inflammatory disease”, Respiration, 75, pp. 224-238.
89.Vanfleteren L, Franssen F, Spruit M.A et al (2011), “Determinants of carotid intima-media thickness in patients with COPD: The Ciroco Study”, Am J Respir Crit Care Med, 183, A2608.
90.Winterborn M.H, Bradwell A.R, Chesner I.M, Jones G.T (1987),“The oirigin of proteinuria at high altitude”, Postgaduate Medical Journal, 63, pp. 179-181.
91.Working Group on Hypercholesterolemia and Other Dyslipidemias
(1998),“Guidelines for lipid testing”, Canadian Journal of Cardiology.
92.Wu S.J, Chen P, Jiang X.N, Liu Z.J et al (2005), “C-reactive protein level
and the correlation between lung function and CRP levels in patients with chronic obstructive pulmonary disease”, Zhong Nan Da Xue Bao Yi Xue Ban, 30 (4), pp. 444-446.
93.Yilmaz M, Domac F.M, Misirli H, Kus D (2009), “Association of inflammatory markers with intima-media thickness and acute ischemic stroke”, J Neurol Sci, 26, pp. 153-164.
94.Yoon J.H, Won J.U, Ahn Y.S et al (2014), “Poor Lung function has inverse relationship with microalbuminuria, an early surrogate marker of kidney damage and atherosclerosis: the 5th Korea National Health and nutrition examination survey”, Plos ONE, 6(4), pp. 1-8.
95.Zureik M, Benetos A, Neukirch C et al (2001), “Reduced pulmonary function is associated with central arterial stiffness in men”, Am J Respir
